About the Company
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Editas Medicine, Inc.
Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch
Editas Medicine Inc. (EDIT) has disclosed a new risk, in the Regulation category. Editas Medicine Inc. faces significant ...
Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business Updates
Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program ...
Charles Schwab Investment Management Inc. Sells 9,031 Shares of Editas ...
Editas Medicine, Inc. has a 52 week low of $1.12 and a 52 week high of $7.41. The company has a market capitalization of $103.72 million, a PE ratio of -0.49 and a beta of 1.88.
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
Editas Medicine, Inc. (NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - Chief ...
Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to ...
In Q1 2024, Editas Medicine, Inc. (NASDAQ:EDIT) reported a net loss of $62.0 million, compared to $49.0 million in Q1 2023, with a net loss per share of $0.76 versus $0.71 in the same period last ...
Raymond James Financial Inc. Takes Position in Editas Medicine, Inc ...
Editas Medicine, Inc. has a 12 month low of $0.91 and a 12 month high of $6.80. Want More Great Investing Ideas? 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 ...
Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ: EDIT) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and Investor Relations Gilmore O ...
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to ...
Editas Medicine, Inc. (NASDAQ:EDIT) sees its in vivo gene-editing platform as a game-changer, with the potential to unlock new therapeutic possibilities and solidify its leadership in the field.
Editas Medicine Announces Chief Financial Officer Transition
--Editas Medicine, Inc., a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025.
Editas Medicine to Host Strategic Update Webinar to Detail Progress ...
CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on ...
EDITAS MEDICINE, INC. Q4 Loss Increases, Misses Estimates
EDITAS MEDICINE, INC. Q4 Loss Increases, Misses Estimates March 05, 2025 — 04:50 pm EST Written by RTTNews.com for RTTNews -> ...
Editas Medicine Announces Chief Financial Officer Transition
CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping ...
Similar Companies
Loading the latest forecasts...